Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
Langenbecks Arch Surg. 2021 May;406(3):773-779. doi: 10.1007/s00423-021-02103-1. Epub 2021 Feb 17.
Systemic inflammation score (SIS) is a novel prognostic score (0, 1, or 2) for various cancers, based on preoperative serum albumin level and lymphocyte-to-monocyte ratio (LMR); modified SIS (mSIS) uses a different LMR cutoff value and was thought to be a more accurate predictor for cancer prognosis. Here, we assessed the prognostic value of SIS and mSIS in patients who receive hepatic resection for hepatocellular carcinoma (HCC).
We retrospectively evaluated SIS and mSIS of 314 patients after hepatic resection for HCC, against their clinicopathological factors and outcomes, using receiver operating characteristics (ROC) analysis over time.
Among patients with preoperative SIS 2, significantly more HCC specimens were poorly differentiated (P = 0.0281), larger (P = 0.0006), and had more microscopic vascular invasion (P = 0.0136) than the SIS 0-1 group; the mSIS 2 group also had significantly larger tumors (P = 0.0039) than the mSIS 0-1 group. In ROC analysis, SIS was a better predictor of overall survival (OS) and recurrence-free survival (RFS) than mSIS. The SIS 2 group had shorter OS (P = 0.0015) and RFS (P = 0.0065) than other patients. In multivariate analysis, SIS 2 was an independent risk factor for shorter OS (hazard ratio (HR) 1.53, P = 0.0497) and RFS (HR 1.58, P = 0.0053).
SIS is superior to mSIS in predicting prognosis of patients with HCC. mSIS is not a great predictor of prognosis in resected HCC.
基于术前血清白蛋白水平和淋巴细胞与单核细胞比值（LMR），全身炎症评分（SIS）是一种针对多种癌症的新型预后评分（0、1 或 2）；改良 SIS（mSIS）采用不同的 LMR 截断值，被认为是更准确的癌症预后预测指标。在这里，我们评估了 SIS 和 mSIS 在接受肝切除术治疗肝细胞癌（HCC）患者中的预后价值。
我们回顾性评估了 314 例接受 HCC 肝切除术患者的 SIS 和 mSIS，根据时间内的 ROC 分析，将其与临床病理因素和结局进行比较。
在术前 SIS 为 2 的患者中，HCC 标本明显更多表现为低分化（P=0.0281）、更大（P=0.0006）和更多的微血管侵犯（P=0.0136），而 SIS 为 0-1 组；mSIS 为 2 组的肿瘤也明显更大（P=0.0039）。在 ROC 分析中，SIS 是总生存（OS）和无复发生存（RFS）的更好预测指标，优于 mSIS。SIS 2 组的 OS（P=0.0015）和 RFS（P=0.0065）均明显短于其他患者。在多变量分析中，SIS 2 是 OS（HR 1.53，P=0.0497）和 RFS（HR 1.58，P=0.0053）较短的独立危险因素。
SIS 在预测 HCC 患者预后方面优于 mSIS。mSIS 不是预测 HCC 切除术后患者预后的良好指标。
